Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as fatty liver disease, has become the most common liver condition seen in gastroenterology clinics today. At Gutcare, many patients come to us after a routine health screening shows fatty liver on ultrasound, even though they feel perfectly well.
The underlying issue is usually metabolic health, particularly obesity and insulin resistance. Over the last few years, a new class of medications—GLP-1 receptor agonists such as semaglutide—has changed how doctors think about treating both obesity and fatty liver disease.
Recent regulatory developments, including the approval of higher semaglutide dosing up to 7.2 mg weekly, are generating excitement because they may help patients achieve greater weight loss and potentially improve liver scarring.
In this article, we explain what semaglutide is, how it works, and why it may play an important role in the treatment of MASLD and liver fibrosis.
What Is MASLD (Fatty Liver Disease)?
MASLD occurs when excess fat accumulates in the liver, usually due to metabolic conditions such as:
- Obesity
- Type 2 diabetes
- High cholesterol
- High blood pressure
- Insulin resistance
The condition exists on a spectrum.
Early disease involves fat deposition in the liver (steatosis). In some patients, this progresses to metabolic dysfunction-associated steatohepatitis (MASH), where inflammation and liver injury occur.
Over time, ongoing inflammation can lead to fibrosis, which is the development of scar tissue in the liver. Advanced fibrosis can eventually progress to cirrhosis and liver failure.
The challenge with MASLD is that it often produces no symptoms until late stages, which is why early treatment is important.
Why Weight Loss Is the Key Treatment for Fatty Liver
Weight loss remains the most effective therapy for MASLD and MASH.
Research consistently shows that:
- 5–7% weight loss reduces liver fat
- 10% weight loss can resolve liver inflammation
- 10–15% weight loss may improve or reverse liver fibrosis
However, achieving and sustaining this degree of weight loss through lifestyle changes alone can be extremely difficult. Many patients struggle despite their best efforts with diet and exercise.
This is where medications such as semaglutide have become increasingly important.
What Is Semaglutide?
Semaglutide is a medication that belongs to a class called GLP-1 receptor agonists.
These drugs mimic a hormone produced in the gut after eating. They help regulate metabolism by:
- Reducing appetite and food cravings
- Increasing feelings of fullness
- Slowing stomach emptying
- Improving insulin sensitivity
- Lowering blood sugar levels
The result for many patients is significant and sustained weight loss, which can improve a range of metabolic conditions including diabetes, cardiovascular risk, and fatty liver disease.
Semaglutide is given as a once-weekly injection, which many patients find convenient.
Semaglutide and Liver Fibrosis: A Major Advance
Historically, gastroenterologists had very limited medication options to treat MASH and liver fibrosis.
Recent clinical trials have shown encouraging results with semaglutide.
In large studies of patients with MASH and liver fibrosis, treatment with semaglutide led to:
- Resolution of liver inflammation in a significant proportion of patients
- Improvement in liver fibrosis in many patients
- Substantial weight loss and metabolic improvement
These findings led to regulatory approval of semaglutide for patients with MASH and moderate-to-advanced fibrosis without cirrhosis.
For liver specialists, this represents a major milestone because it suggests that fibrosis progression may be slowed—or even reversed—in some patients.
What Is the New 7.2 mg Weekly Dose?
Most patients are familiar with semaglutide doses used for weight management, which typically reach 2.4 mg once weekly.
More recently, regulators have approved higher dosing up to 7.2 mg weekly for certain patients with obesity.
The higher dose is typically achieved by administering three 2.4 mg injections on the same day, when clinically appropriate.
The reason for exploring higher doses is simple: greater weight loss may translate into greater metabolic and liver benefits.
How Much Weight Loss Can Semaglutide Achieve?
Clinical trials of semaglutide for obesity have demonstrated impressive results.
At standard doses, patients typically achieve 15–16% weight loss on average.
Studies evaluating higher doses suggest that 7.2 mg weekly may produce around 18–20% weight loss in some patients.
Nearly half of patients in some trials achieved 20% or more weight reduction, which approaches the metabolic effects seen with certain bariatric surgery procedures.
For patients with MASLD, this degree of weight loss may significantly reduce liver fat, inflammation, and fibrosis progression.
Who May Benefit From Semaglutide Treatment?
Semaglutide may be considered for patients with:
Obesity (BMI ≥30)
or overweight individuals with metabolic complications.
Metabolic dysfunction–associated steatotic liver disease (MASLD)
Metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis
Type 2 diabetes or insulin resistance
Treatment decisions should always be individualised and discussed with a gastroenterologist or metabolic specialist.
Is Semaglutide Safe?
Semaglutide has been widely studied and is generally well tolerated.
The most common side effects include:
- Nausea
- Vomiting
- Diarrhea
- Reduced appetite
- Occasional gallbladder issues
These symptoms are usually temporary and improve as the body adjusts, especially when the medication is started at a low dose and gradually increased.
Your doctor will review your medical history to determine whether semaglutide is appropriate for you.
A New Era in Treating Fatty Liver Disease
MASLD and MASH are rapidly becoming the leading causes of chronic liver disease worldwide, including in Singapore.
For many years, doctors could diagnose fatty liver disease but had limited tools to treat it effectively.
Today, medications such as semaglutide offer a promising strategy that addresses the root cause of the disease: metabolic dysfunction and obesity.
With ongoing research and the availability of higher doses such as 7.2 mg weekly, the potential to achieve meaningful weight loss and even improvement in liver fibrosis is becoming increasingly realistic.
For patients living with fatty liver disease, this represents an important step toward preventing progression to cirrhosis and protecting long-term liver health.
When Should You See a Gastroenterologist?
You should consider specialist evaluation if you have:
- Fatty liver detected on ultrasound
- Persistently abnormal liver blood tests
- Obesity or metabolic syndrome
- Diabetes with suspected fatty liver disease
Early assessment can help determine your risk of liver fibrosis and whether treatments such as semaglutide may be beneficial.
At GUTCARE, our gastroenterology specialists provide comprehensive evaluation and management of fatty liver disease, liver fibrosis, and metabolic digestive disorders.
Written by:
Dr Mark Fernandes
Gastroenterologist
Dr Mark Fernandes specialises in the diagnosis and management of digestive and liver diseases, including hepatitis B, fatty liver disease, cirrhosis, and liver cancer screening.
